The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.
The institute will bring together top scientists and clinicians to lead exceptional discovery, translational and clinical...
According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory...
ABSTRACT: 1476O
BARCELONA, Spain ― Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium,...
Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according to new research from The University of Texas MD Anderson Cancer Center.
The preclinical findings, published today in Cancer Cell, represent the first evidence that engineering NK cells, a type of innate immune cell, to secrete...
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly...
ABSTRACTS: 6504, 6507
Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two...
Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to...
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery...
Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with...
Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson...